Targovax ASA logo

TRVX - Targovax ASA Share Price

NOK6.45 -0.1  -1.2%

Last Trade - 05/08/20

Micro Cap
Market Cap £41.8m
Enterprise Value £36.2m
Revenue £216k
Position in Universe 1007th / 1782
Unlock TRVX Revenue
Relative Strength (%)
1m -5.57%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -45.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.072 0.15 0.037 0.037 0.027 2.25 3.50 4.75 +98.8%
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Targovax ASA revenues increased from NOK6K to NOK318K. Net loss decreased 37% to NOK25.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects External R&D Expenses decrease of 38% to NOK12M (expense), Other Operating Expenses decrease of 48% to NOK3.4M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


TRVX Revenue Unlock TRVX Revenue

Net Income

TRVX Net Income Unlock TRVX Revenue

Normalised EPS

TRVX Normalised EPS Unlock TRVX Revenue

PE Ratio Range

TRVX PE Ratio Range Unlock TRVX Revenue

Dividend Yield Range

TRVX Dividend Yield Range Unlock TRVX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
TRVX EPS Forecasts Unlock TRVX Revenue
Profile Summary

Targovax ASA is a Norway-based company active within the healthcare sector. The Company is developing two complementary and targeted approaches in immuno-oncology: a peptide-based immunotherapy platform for patients with RAS-mutated cancers and a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors. The Company's candidate, TG01, is a peptide vaccine that targets mutations in the RAS genes that are associated with cancer, and it is in a phase II clinical trial in pancreatic cancer. The Company's other RAS targeting immunotherapy, TG02 is developed for colorectal cancer treatment. The Company's adenoviral candidate, ONCOS-102 is developed for the treatment of solid tumors, such as melanoma as well as ovarian and prostate cancer.

Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated November 9, 2010
Public Since June 16, 2014
No. of Shareholders: 5,007
No. of Employees: 20
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Oslo Stock Exchange
Shares in Issue 76,087,492
Free Float (0.0%)
Eligible for
TRVX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for TRVX
Upcoming Events for TRVX
Thursday 20th August, 2020
Q2 2020 Targovax ASA Earnings Call
Thursday 20th August, 2020
Q2 2020 Targovax ASA Earnings Call
Thursday 5th November, 2020
Q3 2020 Targovax ASA Earnings Call
Frequently Asked Questions for Targovax ASA
What is the Targovax ASA share price?

As of 05/08/20, shares in Targovax ASA are trading at NOK6.45, giving the company a market capitalisation of £41.8m. This share price information is delayed by 15 minutes.

How has the Targovax ASA share price performed this year?

Shares in Targovax ASA are currently trading at NOK6.45 and the price has moved by 11.37% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Targovax ASA price has moved by 16.31% over the past year.

What are the analyst and broker recommendations for Targovax ASA?

Of the analysts with advisory recommendations for Targovax ASA, there are there are currently 1 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Targovax ASA is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Targovax ASA next release its financial results?

Targovax ASA is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Targovax ASA dividend yield?

Targovax ASA does not currently pay a dividend.

Does Targovax ASA pay a dividend?

Targovax ASA does not currently pay a dividend.

When does Targovax ASA next pay dividends?

Targovax ASA does not currently pay a dividend.

How do I buy Targovax ASA shares?

To buy shares in Targovax ASA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Targovax ASA?

Shares in Targovax ASA are currently trading at NOK6.45, giving the company a market capitalisation of £41.8m.

Where are Targovax ASA shares listed? Where are Targovax ASA shares listed?

Here are the trading details for Targovax ASA:

Country of listing: Norway
Exchange: OSL
Ticker Symbol: TRVX
What kind of share is Targovax ASA?

Based on an overall assessment of its quality, value and momentum, Targovax ASA is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Targovax ASA share price forecast 2020?

Shares in Targovax ASA are currently priced at NOK6.45. At that level they are trading at 0.144% discount to the analyst consensus target price of 0.00.

Analysts covering Targovax ASA currently have a consensus Earnings Per Share (EPS) forecast of -2.109 for the next financial year.

How can I tell whether the Targovax ASA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Targovax ASA. Over the past six months, the relative strength of its shares against the market has been 4.76%. At the current price of NOK6.45, shares in Targovax ASA are trading at -1.95% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Targovax ASA PE Ratio?

We were not able to find PE ratio data for Targovax ASA.

Who are the key directors of Targovax ASA?

Targovax ASA's management team is headed by:

Jon Eriksen - COO
Bente-Lill Bjerkelund Romoren - DRC
Johan Christenson - DRC
Robert Burns - DRC
Eva-Lotta Allan - DRC
Diane Mellett - DRC
Oystein Soug - CEO
Antti Vuolanto - EVP
Tina Madsen - VPR
Anne Aksnes - VPR
Nikolaj Knudtzon - DHR
Peter Skorpil - VBD
Erik Digman Wiklund - OTH
Patrick Vink - CHM
Torbjorn Furuseth - CFO
Victor Levitsky - CSO
Who are the major shareholders of Targovax ASA?

Here are the top five shareholders of Targovax ASA based on the size of their shareholding:

HealthCap AB Venture Capital
Percentage owned: 16.3% (12.4m shares)
Radiumhospitalets Forskningsstiftelse Corporation
Percentage owned: 5.82% (4.43m shares)
Nordea Funds Oy Investment Advisor
Percentage owned: 4.82% (3.66m shares)
Nordea Kapital Mutual Fund
Percentage owned: 2.38% (1.81m shares)
Nordea Avkastning Mutual Fund
Percentage owned: 2.19% (1.67m shares)
Similar to TRVX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.